← Back to Search

Sodium-glucose cotransporter 2 (SGLT2) inhibitor

Active for Coronary Artery Disease (CANTORSING Trial)

Phase 2 & 3

Waitlist Available

Led By Kevin Boczar, MD

Research Sponsored by Ottawa Heart Institute Research Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Stable CAD (over 60 days post-myocardial infarction)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

CANTORSING Trial Summary

This trial is a small study to see if a medication called canagliflozin can reduce inflammation in the arteries of patients with heart disease. They will compare the effects of canaglif

Who is the study for?

This trial is for people who have stable coronary artery disease (CAD) at least 60 days after a heart attack and also have type 2 diabetes. Participants must be willing to give informed consent.Check my eligibility

What is being tested?

The study compares Canagliflozin, a medication given daily, with a placebo over six months to see if it reduces inflammation in the blood vessels of patients with CAD and diabetes.See study design

What are the potential side effects?

Canagliflozin may cause side effects like yeast infections, urination issues, and possibly an increased risk of bone fractures or lower limb amputations.

CANTORSING Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I had a heart attack over 2 months ago and my heart condition has been stable since.

CANTORSING Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

TBR (Tissue-to-blood ratio) of the most-diseased segment (MDS) of the ascending aorta

Secondary outcome measures

Change in inflammatory biomarkers

Change in monocyte marker expression

CANTORSING Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: ActiveActive Control1 Intervention

Canagliflozin 300mg PO daily

Group II: PlaceboPlacebo Group1 Intervention

Placebo PO daily

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ottawa Heart Institute Research CorporationLead Sponsor

188 Previous Clinical Trials

92,412 Total Patients Enrolled

49 Trials studying Coronary Artery Disease

37,872 Patients Enrolled for Coronary Artery Disease

Kevin Boczar, MDPrincipal InvestigatorOttawa Heart Institute Research Corporation

1 Previous Clinical Trials

115 Total Patients Enrolled

Gary Small, MD, PhDPrincipal InvestigatorOttawa Heart Institute Research Corporation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients currently able to enroll in this ongoing medical study?

"Recruitment for this clinical trial has concluded. The initial posting date was 5/1/2024, and the last update occurred on 4/19/2024. For those seeking alternative trials, there are currently 1646 investigations targeting individuals with coronary artery disease in progress, along with two studies actively searching for participants."

Answered by AI

What is the upper limit for the number of participants who can be enrolled in this research endeavor?

"At present, this investigation is not actively seeking individuals to enroll. The study was initially made available on May 1st, 2024 and was most recently revised on April 19th, 2024. Should you be investigating other opportunities, there are currently a total of 1646 studies eagerly seeking participants with coronary artery disease as well as two ongoing trials specifically in the recruitment phase."

Answered by AI

For what medical conditions is Active commonly prescribed?

"Active is a versatile medication commonly prescribed for congestive heart failure. Additionally, it shows promise in managing diabetic nephropathy, promoting physical activity, and addressing type 2 diabetes."

Answered by AI

Are there any previous research investigations that have focused on Active?

"Currently, there are 2 active investigations exploring Active with one trial in Phase III. While the majority of these inquiries are based in Ottawa, Ontario, there are two distinct sites conducting research on this compound."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Canagliflozin Targeting Vascular Inflammation

2024. "Canagliflozin Targeting Vascular Inflammation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05427084.

All > Coronary Artery Disease